CY1106503T1 - Τροποποιηση αλλεργικης αντιδρασης - Google Patents

Τροποποιηση αλλεργικης αντιδρασης

Info

Publication number
CY1106503T1
CY1106503T1 CY20071100500T CY071100500T CY1106503T1 CY 1106503 T1 CY1106503 T1 CY 1106503T1 CY 20071100500 T CY20071100500 T CY 20071100500T CY 071100500 T CY071100500 T CY 071100500T CY 1106503 T1 CY1106503 T1 CY 1106503T1
Authority
CY
Cyprus
Prior art keywords
modification
allergic reaction
elimination
possibility
side effects
Prior art date
Application number
CY20071100500T
Other languages
English (en)
Inventor
Thomas M. Kundig
Stephen J. Mccormack
Original Assignee
Mannkind Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mannkind Corporation filed Critical Mannkind Corporation
Publication of CY1106503T1 publication Critical patent/CY1106503T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/35—Allergens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/81—Drug, bio-affecting and body treating compositions involving autoimmunity, allergy, immediate hypersensitivity, delayed hypersensitivity, immunosuppression, immunotolerance, or anergy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pulmonology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Η τροποποίηση ή εξάλειψη μιας αλλεργικής κατάστασης σύμφωνα με την εφεύρεση επιτυγχάνεται με την έγχυση μικρών ποσοτήτων αλλεργιογόνου απευθείας μέσα σε λεμφαδένα, γεγονός που μειώνει σημαντικά την πιθανότητα εμφάνισης παρενεργειών.
CY20071100500T 2000-10-05 2007-04-10 Τροποποιηση αλλεργικης αντιδρασης CY1106503T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US23772400P 2000-10-05 2000-10-05
US09/804,464 US6773695B2 (en) 2000-10-05 2001-03-13 Modulation of allergic response
PCT/US2001/031088 WO2002028429A2 (en) 2000-10-05 2001-10-05 Modulation of allergic response

Publications (1)

Publication Number Publication Date
CY1106503T1 true CY1106503T1 (el) 2012-01-25

Family

ID=26930958

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20071100500T CY1106503T1 (el) 2000-10-05 2007-04-10 Τροποποιηση αλλεργικης αντιδρασης

Country Status (10)

Country Link
US (1) US6773695B2 (el)
EP (1) EP1322330B1 (el)
AU (2) AU9658701A (el)
CA (1) CA2425740C (el)
CY (1) CY1106503T1 (el)
DE (1) DE60125961T2 (el)
DK (1) DK1322330T3 (el)
ES (1) ES2281447T3 (el)
PT (1) PT1322330E (el)
WO (1) WO2002028429A2 (el)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60223037T2 (de) 2001-08-16 2008-07-24 Cmp Therapeutics Ltd. Chitin-mikropartikel und ihre medizinische verwendung
PL1635863T3 (pl) * 2003-06-17 2011-01-31 Mannkind Corp Kompozycje do wywoływania, wzmacniania i utrzymywania odpowiedzi immunologicznych na epitopy ograniczone do MHC klasy I do celów profilaktycznych i leczniczych
ES2246695B1 (es) * 2004-04-29 2007-05-01 Instituto Cientifico Y Tecnologico De Navarra, S.A. Composicion estimuladora de la respuesta inmunitaria que comprende nanoparticulas a base de un copolimero de metil vinil eter y anhidrido maleico.
AU2012201956B2 (en) * 2004-12-29 2013-10-10 Mannkind Corporation Methods to trigger, maintain and manipulate immune responses by targeted administration of biological response modifiers into lymphoid organs
SG158154A1 (en) * 2004-12-29 2010-01-29 Mannkind Corp Methods to elicit, enhance and sustain immune responses against mhc class i-restricted epitopes, for prophylactic or therapeutic purposes
EP2351577A1 (en) 2004-12-29 2011-08-03 Mannkind Corporation Methods to trigger, maintain and manipulate immune responses by targeted administration of biological response modifiers into lymphoid organs
EP1792627A1 (en) * 2005-12-05 2007-06-06 ImVisioN AG Modulation of the immune response by administration of intralymphatic transduction allergen (ITAG-)-molecules
WO2007065633A1 (en) * 2005-12-05 2007-06-14 Imvision Ag Modulation of the immune response by administration of intralymphatic transduction allergen (itag) -molecules
FR2924349B1 (fr) 2007-12-03 2010-01-01 Dbv Tech Methode de desensibilitation aux allergenes
WO2010103116A2 (en) * 2009-03-13 2010-09-16 Dbv Technologies Method of treating eczema
AU2012301814A1 (en) * 2011-08-31 2014-02-27 Perosphere Technologies Inc. Methods for effectively and rapidly desensitizing allergic patients
WO2014145906A2 (en) * 2013-03-15 2014-09-18 Phd Preventative Health Care And Diagnostics, Inc. A prefilled medication device, method of making and using the same
CA2924714C (en) * 2013-09-19 2024-04-09 Allovate, Llc Toothpaste for delivering allergens to oral mucosa
US10872313B2 (en) 2015-06-02 2020-12-22 ROCA Medical Ltd. Method for repurposing NDC codes in a pharmaceutical database for venom derived allergens involved in venom immunotherapy
US10548974B2 (en) 2015-06-02 2020-02-04 ROCA Medical Ltd. Therapeutic treatment kit for allergies based on DNA profiles
US20160362205A1 (en) * 2015-06-02 2016-12-15 ROCA Medical Ltd. Use of autoinjector for distributing antigens to the public
US10369215B2 (en) 2015-06-02 2019-08-06 ROCA Medical Ltd. Predilution sets for distributing antigens
US10441209B2 (en) * 2016-02-04 2019-10-15 ROCA Medical Ltd. Antigen regional testing kit
CN107266532B (zh) * 2016-04-06 2020-06-16 暨南大学 一种新多肽pap1及其应用
DE102018113509A1 (de) 2018-06-06 2019-12-12 Philipps-Universität Marburg Mikroemulsion zur dermalen Hyposensibilisierung mit Allergenen
CN111821444A (zh) * 2018-11-28 2020-10-27 苏州致和结构医药科技有限公司 一种治疗和/或预防枫树花粉过敏性疾病的物质及其设计方法和制备方法
US20230381302A1 (en) 2020-10-14 2023-11-30 Aarhus Universitet Treatment protocol using intralymphatic immunotherapy

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3849551A (en) 1972-09-28 1974-11-19 Antonio L D Bcg as adjuvant in malaria vaccination
US5593877A (en) 1993-03-11 1997-01-14 The Rockefeller University Nucleic acid and recombinant production of vespid venom hyaluronidase
US5804201A (en) 1996-03-11 1998-09-08 The Rockefeller University Immunomodulatory peptides of vespid antigen 5
ES2438735T3 (es) 1997-07-10 2014-01-20 Mannkind Corporation Inmunización intralinfática para inducir respuestas de CTL efectores prolongadas
WO2000050044A1 (en) 1999-02-25 2000-08-31 Tai June Yoo Vaccine for house dust mite allergen using naked plasmid dna
WO2001082963A2 (en) 2000-04-28 2001-11-08 Ctl Immunotherapies Corp. Method of identifying and producing antigen peptides and use thereof as vaccines

Also Published As

Publication number Publication date
EP1322330A2 (en) 2003-07-02
WO2002028429A2 (en) 2002-04-11
AU2001296587B2 (en) 2006-08-31
DK1322330T3 (da) 2007-05-14
DE60125961T2 (de) 2007-10-11
WO2002028429A9 (en) 2003-10-30
US6773695B2 (en) 2004-08-10
US20020061315A1 (en) 2002-05-23
CA2425740C (en) 2016-05-03
EP1322330B1 (en) 2007-01-10
DE60125961D1 (de) 2007-02-22
PT1322330E (pt) 2007-04-30
ES2281447T3 (es) 2007-10-01
AU9658701A (en) 2002-04-15
WO2002028429A3 (en) 2002-10-10
CA2425740A1 (en) 2002-04-11

Similar Documents

Publication Publication Date Title
CY1106503T1 (el) Τροποποιηση αλλεργικης αντιδρασης
BRPI0411897A (pt) pirroldihidroisoquinolinas como inibidores de pde10
TR199701146T1 (xx) N�rotensin resept�rleri �zerinde etkili 1-Fenilpirazol-3-Karboksamidler.
CY1109886T1 (el) Καινοφανεις ενωσεις ως αντι-φλεγμονωδεις, ανοσοτροποποιητικοι και αντι υπερπλαστικοι παραγοντες
CY1110933T1 (el) 5,7-διαμινοπυραζολο[4,3-d]πυριμιδινες με ανασταλτικη της pde-5 δραστικοτητα
CY1115713T1 (el) Παραγωγα ακρυλαμιδιου ως αντιβιοτικοι παραγοντες
DE602004031372D1 (de) Nachweis von staphylococcus
ATE403429T1 (de) Spiropyrazol-verbindungen
HN1999000125A (es) Nuevos derivados sustituidos del pirazol
CY1106247T1 (el) Θειοφαινο- και θειαζολοσουλφοναμιδες ως αντινεοπλαστικοι παραγοντες
CR8268A (es) Compuesto de aril o heteroaril amida como antogonistas del receptor de prostaglandina e2
DE60230890D1 (de) Indolizine als kinaseproteinhemmer
CY1108567T1 (el) Αντιθρομβωτικες ενωσεις
CR7182A (es) Benzoilsufanamidas y sulfonilbenzamidinas que se usan como agentes antitumorales
DE60235900D1 (de) Osuppressivum
CY1110064T1 (el) Παραγωγα φαινυλ-πιπεραζινης ως αναστολεις επαναπροσληψης σεροτονινης
CY1105337T1 (el) Πρωτοτυπες διυδροπτepιδινονες, μεθοδος για την παραγωγη τους και η χρηση τους ως φαρμακευτικα μεσα
HRP20030383B1 (en) Lactam compound
CY1113578T1 (el) 2,3-διυδρο-6-νιτροϊμιδαζο 2,1 -b-οξαζολια
CY1107503T1 (el) Αντιβιοτικα διπλης δρασης
CY1112467T1 (el) Παραγωγα 1-θειο-d-γλυκιτολης
CY1111567T1 (el) Ενδιαμεσα διβενζο (b,f) αζεπινης
CY1111978T1 (el) Συζυγη μακρολιδων με αντιφλεγμονωδη δραση
CY1107485T1 (el) 3-θειομεθυλπυραζoλες ως παρασιτοκτoνα
ATE417849T1 (de) Pyrazoloä4,3-düpyrimidine